Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xianlingcao granules plus chemotherapy in primary non-small cell lung cancer
CTR20170065Phase 2Active
- Sponsor
- Tianjin Tianjiao Pharmaceutical
- Start
- Aug 2017
- Countries
- 1
01
Overview
A Phase 2 trial of xianlingcao in non-small cell lung cancer (NSCLC), sponsored by Tianjin Tianjiao Pharmaceutical. Started Aug 2017; status: active.
02
Drugs
xianlingcao
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20170065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170065.